Side by side
CJC-1295 vs FOXO4-DRI
Both are discussed for anti-aging & longevity. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| CJC-1295 | FOXO4-DRI | |
|---|---|---|
| What it is | A GHRH analogue that raises growth hormone by amplifying the body's own release signal. Sold in two forms whose durations differ by two orders of magnitude. | A senolytic peptide that made aged mice regrow fur and recover kidney function. One landmark paper, no human trial, and it works by making cells kill themselves. |
| EvidenceHow much human evidence exists, not how well it works. | Early human trials | Preclinical |
| Regulatory statusReviewed 2026-08-12 | Not approved for human use in the United States. The FDA has identified CJC-1295 as a substance raising concerns for use in compounded preparations. Sold only as a research chemical. | Not approved anywhere and never studied in a human trial. Other senolytic agents have entered early human trials; this peptide has not. Sold only as a research chemical. |
| Routes | Subcutaneous | Subcutaneous, Intravenous |
| Half-life | 0.5 hours | Not recorded |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $2.40/mg | $6.26/mg |
| Median per mg | $7.25/mg | $17.50/mg |
| Vendors with a price | 40 | 18 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze once mixed. | Refrigerated at 2–8 °C. Do not freeze once mixed. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.